Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
188 shown of 2,462 total abstracts
  1. Abstract 10442026-09-01 · 20:30 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    H. Borghaei, H. Rugo, P. Schmid · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 11572026-09-04 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-154 study)
    S. Antonia, M. Reck, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 13602026-09-05 · 14:45 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    M. Reck, C. Saura, R. Herbst, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 18422026-09-05 · 14:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-60
    C. Robert, J. Cortes, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 18802026-09-04 · 16:00 CT · E450
    ASCENT-374: Trodelvy (sacituzumab govitecan) 1L in TNBC
    A. Spira, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 16182026-09-01 · 20:15 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    N. Rizvi, M.C. Garassino, S. Peters, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 12772026-09-05 · 16:15 CT · S406
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-748
    M. Krop, R. Herbst · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 16192026-09-02 · 14:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with TNBC
    L. Paz-Ares, R. Herbst, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 15082026-09-04 · 18:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-755 study)
    S. Peters, S. Tolaney, F. Andre, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 11732026-09-02 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-639
    M. Reck, H. Rugo, N. Rizvi · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 11552026-09-04 · 16:00 CT · Arie Crown Theater
    MONARCH-2: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    N. Rizvi, M. Krop, C. Saura, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 15342026-09-05 · 20:30 CT · S406
    IMpower-172: Tecentriq (atezolizumab) 3L+ in TNBC
    R. Herbst, J. Brahmer · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 19082026-09-03 · 16:00 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Peters, P. Schmid · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 10322026-09-02 · 19:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-747
    T. Mok, J. Cortes, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 11322026-09-03 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-892 study)
    L. Paz-Ares, M. Reck, S. Modi, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 18582026-09-02 · 14:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-79
    G. Curigliano, A. Spira, M.C. Garassino, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 13102026-09-04 · 16:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-183
    G. Curigliano, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 16482026-09-02 · 13:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-912
    M. Reck, E. Winer, H. Borghaei, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 10082026-09-05 · 13:15 CT · Arie Crown Theater
    MONARCH-420: Verzenio (abemaciclib) 1L in HR+ breast cancer
    H. Borghaei, H. Rugo, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 13912026-09-05 · 18:45 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-11
    R. Herbst, S. Peters, S. Antonia · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 18182026-09-02 · 20:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-226 study)
    A. Spira, H. Borghaei, R. Herbst, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 19972026-09-03 · 20:45 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    L. Paz-Ares, E. Winer, N. Rizvi, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 18722026-09-05 · 19:00 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    H. Borghaei, C. Saura, E. Winer · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 18732026-09-01 · 21:30 CT · Hall B1
    OlympiA-842: Lynparza (olaparib) 3L+ in HR+ breast cancer
    J. Brahmer, G. Curigliano, T. Mok, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 19592026-09-03 · 18:15 CT · S100A
    OlympiA-436: Lynparza (olaparib) 3L+ in HR+ breast cancer
    L. Paz-Ares, M.C. Garassino, P. Schmid · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 11322026-09-02 · 15:45 CT · Hall B1
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-513
    E. Winer, M. Krop, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 16922026-09-04 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-486 study)
    C. Robert, R. Herbst, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 15952026-09-01 · 18:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-538 study)
    S. Peters, S. Antonia, M. Reck, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 13342026-09-04 · 21:00 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-580 study)
    S. Modi, M. Krop, J. Cortes · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 19362026-09-04 · 15:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-79 study)
    A. Spira, P. Schmid, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 14302026-09-03 · 20:00 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    J. Brahmer, J. Cortes · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 18262026-09-04 · 16:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-412
    J. Brahmer, R. Herbst · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 13652026-09-01 · 14:15 CT · Arie Crown Theater
    OlympiA-25: Lynparza (olaparib) maintenance in HR+ breast cancer
    T. Mok, H. Rugo, G. Curigliano, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 15902026-09-05 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-27 study)
    S. Antonia, S. Modi, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 19572026-09-02 · 14:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-682
    A. Spira, E. Winer, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 17042026-09-01 · 16:45 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-391
    J. Cortes, M. Krop, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 15552026-09-03 · 14:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-677
    L. Paz-Ares, C. Robert · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 18202026-09-01 · 21:45 CT · Hall B1
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-939
    M.C. Garassino, R. Herbst, T. Mok, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 12952026-09-02 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-734
    N. Rizvi, G. Curigliano, E. Winer · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 19092026-09-05 · 21:45 CT · S406
    MONARCH-371: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    S. Tolaney, J. Brahmer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 16712026-09-01 · 18:00 CT · S100A
    ASCENT-781: Trodelvy (sacituzumab govitecan) 2L in TNBC
    C. Robert, P. Schmid, N. Rizvi, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 14442026-09-04 · 13:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-89
    M.C. Garassino, E. Winer · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 14312026-09-05 · 18:45 CT · S100A
    MONALEESA-388: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    N. Rizvi, E. Winer, S. Antonia, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 17892026-09-04 · 18:45 CT · Hall B1
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-331
    H. Rugo, A. Spira, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 18762026-09-03 · 14:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-674 study)
    M. Krop, A. Spira · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 12292026-09-01 · 14:15 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    J. Brahmer, M.C. Garassino, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 13822026-09-04 · 21:45 CT · S100A
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-199
    J. Cortes, E. Winer, C. Robert · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 16242026-09-02 · 20:15 CT · Arie Crown Theater
    OlympiA-106: Lynparza (olaparib) 1L in HR+ breast cancer
    H. Rugo, M. Krop · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 17262026-09-01 · 14:45 CT · S406
    MONALEESA-128: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Antonia, S. Tolaney, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 11322026-09-01 · 19:15 CT · S100A
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-150
    M.C. Garassino, J. Cortes · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 15882026-09-04 · 18:15 CT · E450
    MONALEESA-735: Kisqali (ribociclib) 2L in HR+ breast cancer
    C. Robert, C. Saura, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 11452026-09-02 · 16:15 CT · E450
    PALOMA-812: Ibrance (palbociclib) 2L in HR+ breast cancer
    T. Mok, S. Modi, C. Saura, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 10362026-09-02 · 20:30 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Tolaney, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 18932026-09-03 · 15:45 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-754
    C. Robert, A. Spira · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 18262026-09-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-389
    R. Herbst, S. Tolaney, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 13882026-09-05 · 16:45 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-169
    S. Modi, C. Saura · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 19872026-09-03 · 19:30 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-978
    M. Reck, C. Robert · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 19342026-09-01 · 21:15 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    A. Spira, C. Robert · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 18192026-09-05 · 13:30 CT · Hall B1
    MONALEESA-182: Kisqali (ribociclib) 1L in HR+ breast cancer
    S. Tolaney, M. Krop, E. Winer, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 11322026-09-02 · 16:30 CT · S100A
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-322
    E. Winer, C. Robert, M.C. Garassino, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 14572026-09-02 · 19:30 CT · S100A
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-935
    T. Mok, S. Tolaney, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 10662026-09-05 · 20:00 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Tolaney, M. Reck, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 15832026-09-05 · 15:30 CT · S406
    MONARCH-441: Verzenio (abemaciclib) 1L in HR+ breast cancer
    F. Andre, M. Krop, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 14552026-09-05 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-420 study)
    S. Peters, C. Robert · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 19372026-09-02 · 16:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-544 study)
    L. Paz-Ares, H. Borghaei, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 18472026-09-04 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-885
    J. Cortes, H. Borghaei, A. Spira, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 10632026-09-03 · 16:15 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-103
    E. Winer, C. Robert, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 13172026-09-04 · 16:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-434
    A. Spira, N. Rizvi, J. Brahmer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 16652026-09-01 · 19:45 CT · Hall B1
    OlympiA-448: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    M. Krop, E. Winer · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 19642026-09-04 · 13:30 CT · S100A
    MONARCH-738: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    F. Andre, M. Krop, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 12402026-09-04 · 21:30 CT · Hall B1
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-654
    P. Schmid, H. Borghaei · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 11702026-09-02 · 21:30 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    F. Andre, S. Modi, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 11522026-09-02 · 19:15 CT · E450
    DESTINY-Breast-250: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    J. Cortes, A. Spira, H. Rugo · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 13052026-09-03 · 16:45 CT · Arie Crown Theater
    MONALEESA-280: Kisqali (ribociclib) maintenance in HR+ breast cancer
    C. Robert, H. Rugo, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 14062026-09-03 · 16:00 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-82
    H. Borghaei, G. Curigliano, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 18662026-09-01 · 15:15 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-854
    L. Paz-Ares, M. Krop · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 13312026-09-04 · 20:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-326
    A. Spira, R. Herbst, M. Krop, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 14662026-09-01 · 15:45 CT · E450
    MONARCH-27: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    C. Saura, A. Spira, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 14052026-09-04 · 14:00 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-114
    F. Andre, S. Tolaney · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 13142026-09-04 · 20:45 CT · Arie Crown Theater
    IMpower-349: Tecentriq (atezolizumab) adjuvant in TNBC
    C. Saura, A. Spira, M. Krop, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 15332026-09-05 · 13:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-669 study)
    M. Reck, H. Borghaei, H. Rugo, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 18592026-09-04 · 16:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-298
    M. Krop, S. Peters, P. Schmid · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 13012026-09-02 · 18:00 CT · S100A
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-971
    S. Modi, S. Peters · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 17722026-09-04 · 19:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-868 study)
    M. Reck, S. Peters · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 13012026-09-01 · 19:15 CT · Hall B1
    MONALEESA-403: Kisqali (ribociclib) 2L in HR+ breast cancer
    P. Schmid, R. Herbst, S. Tolaney, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 15012026-09-04 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-528 study)
    N. Rizvi, E. Winer, S. Modi · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 11612026-09-01 · 20:00 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-993
    J. Cortes, L. Paz-Ares, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 10292026-09-04 · 15:00 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-927
    G. Curigliano, S. Tolaney, J. Brahmer, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 12622026-09-05 · 20:00 CT · S406
    MONARCH-107: Verzenio (abemaciclib) 1L in HR+ breast cancer
    H. Rugo, M.C. Garassino · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 17782026-09-03 · 15:45 CT · Arie Crown Theater
    OlympiA-230: Lynparza (olaparib) maintenance in HR+ breast cancer
    S. Peters, E. Winer, M. Reck, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 13302026-09-02 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-19 study)
    M. Krop, E. Winer, P. Schmid, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 13422026-09-01 · 15:30 CT · Arie Crown Theater
    MONARCH-236: Verzenio (abemaciclib) 2L in HR+ breast cancer
    R. Herbst, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 15392026-09-04 · 18:00 CT · S100A
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-871
    H. Rugo, M.C. Garassino, S. Tolaney, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 12222026-09-02 · 18:15 CT · Hall B1
    MONARCH-9: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    S. Antonia, M. Krop, H. Rugo, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 16872026-09-03 · 14:45 CT · E450
    MONALEESA-730: Kisqali (ribociclib) maintenance in HR+ breast cancer
    N. Rizvi, T. Mok, J. Cortes, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 16882026-09-01 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-67 study)
    G. Curigliano, N. Rizvi, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 13382026-09-03 · 19:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-264 study)
    E. Winer, M. Krop, C. Saura, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 10902026-09-04 · 16:00 CT · S406
    DESTINY-Breast-269: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    A. Spira, F. Andre, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 11472026-09-03 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-860 study)
    J. Cortes, F. Andre, M. Reck, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 14782026-09-05 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Peters, F. Andre, M. Reck, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 13552026-09-03 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-930
    P. Schmid, M. Reck · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 16112026-09-04 · 16:30 CT · Hall B1
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-558
    J. Cortes, S. Modi, S. Antonia · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 13482026-09-01 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    L. Paz-Ares, F. Andre, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 10322026-09-05 · 16:30 CT · Hall B1
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-142
    J. Brahmer, M. Reck, P. Schmid · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 15092026-09-04 · 21:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-964
    R. Herbst, F. Andre, P. Schmid, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 10862026-09-02 · 19:45 CT · S100A
    PALOMA-430: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    E. Winer, S. Modi, P. Schmid · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 11642026-09-01 · 21:00 CT · S100A
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-686
    S. Modi, F. Andre, M.C. Garassino, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 13212026-09-05 · 15:15 CT · S406
    MONALEESA-27: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    R. Herbst, C. Robert · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 16372026-09-01 · 13:30 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-764
    M.C. Garassino, J. Cortes, J. Brahmer · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 16982026-09-05 · 15:15 CT · S100A
    MONARCH-85: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    C. Robert, T. Mok · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 17842026-09-05 · 21:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-39 study)
    P. Schmid, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 10032026-09-01 · 13:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-933
    J. Cortes, S. Modi · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 16122026-09-01 · 16:15 CT · Arie Crown Theater
    PALOMA-900: Ibrance (palbociclib) maintenance in HR+ breast cancer
    M. Reck, M. Krop, J. Brahmer, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 19272026-09-02 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-961
    A. Spira, T. Mok, G. Curigliano, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 14772026-09-02 · 16:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-241 study)
    M. Reck, F. Andre, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 12502026-09-04 · 15:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-390
    L. Paz-Ares, N. Rizvi, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 11072026-09-05 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-726
    M.C. Garassino, A. Spira, R. Herbst · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 16532026-09-03 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-287
    M. Reck, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract 16052026-09-03 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-514 study)
    C. Saura, S. Peters, F. Andre · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 10702026-09-04 · 20:15 CT · S406
    MONARCH-72: Verzenio (abemaciclib) 2L in HR+ breast cancer
    M. Krop, H. Rugo · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 19942026-09-03 · 18:45 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-547
    N. Rizvi, S. Peters, J. Brahmer, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 13802026-09-04 · 20:15 CT · E450
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-433
    M. Krop, F. Andre, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 16212026-09-01 · 21:15 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-635
    S. Antonia, A. Spira · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 11942026-09-05 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-610
    G. Curigliano, C. Robert, C. Saura, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 13332026-09-03 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-634 study)
    H. Rugo, A. Spira, R. Herbst, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 12332026-09-03 · 16:15 CT · S406
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-648
    S. Antonia, S. Tolaney, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 15612026-09-03 · 13:15 CT · S100A
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-703
    S. Antonia, A. Spira, G. Curigliano, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 15512026-09-03 · 15:30 CT · Hall B1
    PALOMA-204: Ibrance (palbociclib) maintenance in HR+ breast cancer
    L. Paz-Ares, S. Modi, A. Spira · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 15092026-09-01 · 19:00 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-598
    M.C. Garassino, S. Peters, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 16582026-09-02 · 13:30 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-946 study)
    S. Tolaney, F. Andre, S. Peters · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 19382026-09-02 · 20:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-523 study)
    M. Krop, C. Robert · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 18542026-09-02 · 20:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-734
    S. Modi, S. Antonia · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 15302026-09-04 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-540
    N. Rizvi, A. Spira, P. Schmid · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 18332026-09-01 · 14:15 CT · S406
    PALOMA-222: Ibrance (palbociclib) 1L in HR+ breast cancer
    N. Rizvi, P. Schmid, T. Mok · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 13732026-09-03 · 18:45 CT · S100A
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-287
    M. Reck, R. Herbst, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 18892026-09-05 · 19:00 CT · Arie Crown Theater
    MONALEESA-411: Kisqali (ribociclib) 2L in HR+ breast cancer
    C. Robert, M.C. Garassino, M. Krop, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 11922026-09-04 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-732 study)
    P. Schmid, M. Krop · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 12722026-09-04 · 14:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-768
    C. Saura, P. Schmid, T. Mok · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 10012026-09-01 · 20:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-137 study)
    A. Spira, C. Saura · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 11692026-09-02 · 21:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-877
    J. Cortes, T. Mok, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 17482026-09-02 · 19:00 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-671
    H. Borghaei, M. Reck, S. Tolaney · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 17632026-09-02 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-446 study)
    H. Rugo, S. Peters, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 17842026-09-05 · 21:15 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-178
    G. Curigliano, S. Peters, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 11672026-09-01 · 16:15 CT · S100A
    MONARCH-234: Verzenio (abemaciclib) 1L in HR+ breast cancer
    C. Robert, C. Saura, J. Brahmer, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 11312026-09-04 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-722
    L. Paz-Ares, J. Cortes · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 12642026-09-04 · 21:30 CT · Arie Crown Theater
    MONARCH-463: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    R. Herbst, S. Modi, C. Robert · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 15832026-09-02 · 14:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-681
    A. Spira, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 11112026-09-02 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-416 study)
    A. Spira, H. Borghaei, S. Antonia · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 14062026-09-03 · 18:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-29
    L. Paz-Ares, C. Saura, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 19802026-09-02 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-255
    C. Saura, S. Tolaney · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 16402026-09-02 · 13:00 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-983
    S. Tolaney, M. Reck, S. Modi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 19502026-09-04 · 13:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-274
    T. Mok, A. Spira, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 19382026-09-03 · 14:00 CT · S100A
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-816
    F. Andre, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 13762026-09-05 · 18:30 CT · E450
    ASCENT-573: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    S. Modi, G. Curigliano, H. Borghaei · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 12092026-09-04 · 20:45 CT · Hall B1
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-374
    M.C. Garassino, S. Antonia, C. Saura, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 13492026-09-05 · 21:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-300
    C. Saura, S. Tolaney, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 17252026-09-02 · 18:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-48 study)
    S. Peters, H. Rugo, M. Krop · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 10692026-09-04 · 20:00 CT · E450
    MONALEESA-611: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    A. Spira, J. Brahmer, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 13212026-09-01 · 14:15 CT · Hall B1
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-113
    P. Schmid, L. Paz-Ares · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 11602026-09-04 · 21:45 CT · S100A
    MONARCH-236: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    G. Curigliano, H. Rugo, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 18022026-09-03 · 15:45 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-960
    N. Rizvi, H. Borghaei, R. Herbst · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 13032026-09-05 · 21:45 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-602
    A. Spira, P. Schmid, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 15792026-09-05 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-241
    C. Saura, F. Andre, N. Rizvi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 13782026-09-01 · 16:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-783 study)
    H. Rugo, S. Modi · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 14002026-09-05 · 19:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-142
    G. Curigliano, E. Winer · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 13022026-09-01 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-721
    P. Schmid, J. Cortes, S. Peters, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 17202026-09-01 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for TNBC: KEYNOTE-165
    R. Herbst, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 19402026-09-04 · 18:15 CT · Arie Crown Theater
    MONALEESA-29: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    G. Curigliano, R. Herbst, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 12942026-09-02 · 18:30 CT · Arie Crown Theater
    IMpower-699: Tecentriq (atezolizumab) maintenance in TNBC
    M. Reck, T. Mok, H. Borghaei · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 13582026-09-03 · 20:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-873
    H. Rugo, N. Rizvi, E. Winer · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 14262026-09-02 · 21:15 CT · S406
    Long-term follow-up of Keytruda adjuvant for TNBC: KEYNOTE-214
    N. Rizvi, C. Robert, G. Curigliano, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 19422026-09-03 · 21:00 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-904
    S. Peters, J. Brahmer, C. Robert, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 13182026-09-05 · 16:00 CT · S100A
    MONARCH-801: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    P. Schmid, S. Tolaney, F. Andre, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 17312026-09-03 · 19:15 CT · Hall B1
    MONARCH-274: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    L. Paz-Ares, F. Andre, S. Peters · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 16752026-09-05 · 13:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-603
    E. Winer, G. Curigliano, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 13702026-09-03 · 13:30 CT · E450
    MONARCH-506: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    C. Saura, M. Krop · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 17722026-09-01 · 18:45 CT · S100A
    MONALEESA-711: Kisqali (ribociclib) 1L in HR+ breast cancer
    S. Antonia, M. Reck, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 17002026-09-03 · 18:15 CT · S100A
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-177
    H. Borghaei, S. Peters, N. Rizvi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 17642026-09-04 · 14:45 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-102
    J. Brahmer, S. Peters, N. Rizvi · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 11242026-09-02 · 19:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-23
    H. Borghaei, L. Paz-Ares, F. Andre · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 12462026-09-04 · 14:00 CT · S100A
    PALOMA-608: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Saura, L. Paz-Ares, S. Peters · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 11162026-09-03 · 21:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-378 study)
    S. Antonia, H. Borghaei, M. Krop · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 19362026-09-03 · 15:00 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-166
    J. Brahmer, S. Modi, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 17652026-09-05 · 13:30 CT · S406
    IMpower-466: Tecentriq (atezolizumab) neoadjuvant in TNBC
    G. Curigliano, S. Modi, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract 10862026-09-04 · 16:00 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-979 study)
    C. Saura, M.C. Garassino · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 13202026-09-01 · 18:45 CT · S100A
    DESTINY-Breast-958: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    S. Peters, S. Tolaney, S. Modi, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 17822026-09-03 · 20:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-815 study)
    H. Rugo, J. Brahmer, A. Spira, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 16732026-09-05 · 18:15 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-656
    S. Antonia, S. Modi, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.